BCL7A

Across TCGA pan-cancer cohorts, BCL7A RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of BCL7A’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where BCL7A RNA is more highly expressed in tumor relative to normal tissue. In most cancer types BCL7A is over-expressed in tumor, although a few such as KIRC and KICH show the opposite, repressed pattern.

HNSC, COAD, and LIHC are the cancer types where BCL7A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BCL7A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	+1.171	<.001	11	view →
COAD	Female	II,III,IV	+1.158	<.001	11	view →
LIHC	All	II,III,IV	+0.884	<.001	8	view →
KIRC	Male	II,III,IV	−0.803	<.001	8	view →
STAD	Male	II,III,IV	+1.232	<.001	7	view →
LUSC	Female	All	+1.178	<.001	7	view →
BLCA	Male	All	+0.851	<.001	7	view →
LUAD	Male	II,III,IV	+0.568	.005	6	view →
KICH	All	All	−0.573	.002	5	view →
CHOL	Male	All	+2.570	<.001	3	view →
UCEC	All	III,IV	+0.869	.034	2	view →
ESCA	Male	All	+0.675	.031	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

BCL7A–HNSC

Open the HNSC breakdown →